search
Back to results

Aiding COPD and CHF Ultrasound-guided Management Through ENhanced Point Of Care UltraSound (ACCUMEN-POCUS)

Primary Purpose

COPD, CHF, Pneumonia

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Lung point of care ultrasound
PRESUNA software
Sponsored by
Michelle Grinman
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for COPD

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Patient Inclusion Criteria:

  • 18 years of age or older
  • Has a provincial health care number
  • Functionally safe to receive HH care or have sufficient caregiving to support them at home
  • Stable enough to be cared for at home - stable vital signs and requiring no more than 2 visits per day
  • Able and willing to follow a management plan
  • Provides consent to receive care on HH
  • Diagnosis of CHF and/or COPD that requires HH care
  • No painful/broken ribs that could be affected by pressure applied when performing lung POCUS

Patient Exclusion Criteria:

  • Not eligible for HH care
  • New unstable rib fractures
  • Prior history of allergy to ultrasound gel
  • Participant refusal to participate in research study

Provider inclusion criteria

  • Attending clinician on the home hospital program within the next 3-6 months
  • Provides informed consent to participate in the study, including necessary training for the use of POCUS and/or PRESUNA

Provider exclusion criteria

  • Not a home hospital clinician
  • Refuses to consent for the study / training.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    No Intervention

    Arm Label

    POCUS-PRESUNA

    Standard Care

    Arm Description

    Daily home hospital care will be enhanced by lung POCUS acquired remotely by community paramedics or in-person by physicians, and interpreted by physicians. They will then document their findings on PRESUNA to obtain a longitudinal record that enables monitoring of trends to support clinical decision-making.

    Standard home hospital care

    Outcomes

    Primary Outcome Measures

    Length of stay
    Length of stay for index Home Hospital admission

    Secondary Outcome Measures

    Patient outcome - Time to resolution of infection
    return to baseline oxygen saturation and normalization of white blood cell count
    Patient outcome - time to decongestion
    absence of crackles and baseline oxygen saturation on lung examination
    Patient outcome - rate of change in NT-BNP
    Difference between NT-BNP on admission and at time of decongestion over total number of days
    Patient outcome - Admission to facility living
    Proportion of patients in each study arm that required admission to facility living (eg: long-term care, supportive living) after their index admission
    Patient outcome - Escalation of care
    Incidence rate ratio for frequency with which patients are transferred back to the bricks and mortar hospital from the home hospital.
    Patient outcome - Adverse events
    Frequency and severity of adverse events (venous thromboembolism, new infections, falls, delirium)
    Patient outcome - Mortality
    Date and cause of mortality of occurrence of mortality
    Health Related Quality of Life - EuroQuol- 5-Dimension-5-Level (EQ-5D-5L) -Mobility
    The ability to mobilize is rated by patients on a scale from 1-5 (1= no problems, 2= slight problems, 3= moderate problems, 4= Severe problems, 5= Unable to perform activity)
    Health Related Quality of Life - EuroQuol- 5-Dimension-5-Level (EQ-5D-5L) -Activities of daily living
    Ability to perform activities of daily living rated by patients from 1-5 (1= no problems, 2= slight problems, 3= moderate problems, 4= Severe problems, 5= Unable to perform activity)
    Health Related Quality of Life - EuroQuol- 5-Dimension-5-Level (EQ-5D-5L) -Pain and discomfort
    The intensity of pain or discomfort is rated by patients from 1 to 5 (1=none, 2= slight , 3= moderate , 4=severe, 5=extreme).
    Health Related Quality of Life - EuroQuol- 5-Dimension-5-Level (EQ-5D-5L) -Self care
    Ability to perform self-care rated from 1= no problems, 2= slight problems, 3= moderate problems, 4= Severe problems, 5= Unable to perform activity
    Health Related Quality of Life - EuroQuol- 5-Dimension-5-Level (EQ-5D-5L) -Anxiety and Depression
    Patients rate whether they feel anxious or depressed from 1-5 (1=no, 2= slightly, 3= moderately, 4=severely, 5=extremely).
    Health Related Quality of Life - EuroQuol- 5-Dimension-5-Level (EQ-5D-5L) -Index Score
    The index score is computed using the EQ-5D calculator that uses the scores of the individual dimensions (mobility, self-care, activities of daily living, pain and discomfort, anxiety and depression); Scores range between 5-25 with higher scores indicating a worse outcome
    Health Related Quality of Life - EuroQuol- 5-Dimension-5-Level (EQ-5D-5L) Visual Analogue Scale (EQ-VAS)
    Participant asked to rate both verbally and visually "where [they] would put [their] health today" on a scale from 0 ("the worst health you can imagine") to 100 ("the best health you can imagine)
    Patient experience
    Survey measuring experience with clinical care and various technologies employed by the Home Hospital (digital remote patient monitoring, videoconferencing, as well as POCUS for the intervention arm). This survey was developed by the study team. Responses to questions were either, "yes", "yes, to some extent", "no", and "unsure".
    Provider experience
    Surveys including experience providing care for patients on each study arm and experience with various technologies employed in the home hospital program (digital remote patient monitoring, videoconferencing, as well as POCUS and PRESUNA for the intervention arm). This survey was developed by the study team. Responses were on a Likert scale, which included "strongly disagree", "disagree", "neither agree/nor disagree", "agree" and "strongly agree"
    Healthcare utilization cost - Diagnostic testing
    Cost of Diagnostic testing
    Healthcare utilization - Incidence rate ratio of acute care days pre/during/post
    Incidence rate ratio of acute care days in the bricks and mortar hospital 90 days pre-randomization, during the index admission after randomization, and 90 days post discharge from index admission
    Healthcare utilization - Incidence rate ratio of ED/Urgent Care visits pre/during/post
    Incidence rate ratio of ED and urgent care visits- 90 days pre-randomization, during the index admission after randomization, and 90 days post discharge from index admission
    Cost analysis
    Incremental effectiveness ratio for the index admission
    Cost analysis
    Incremental effectiveness ratio for healthcare utilization post-discharge

    Full Information

    First Posted
    May 5, 2022
    Last Updated
    December 5, 2022
    Sponsor
    Michelle Grinman
    Collaborators
    PRESUNA, Institute of Health Economics, Canada, Alberta Boehringer Ingelheim Collaboration
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05423652
    Brief Title
    Aiding COPD and CHF Ultrasound-guided Management Through ENhanced Point Of Care UltraSound
    Acronym
    ACCUMEN-POCUS
    Official Title
    Aiding COPD and CHF Ultrasound-guided Management Through ENhanced Point Of Care UltraSound
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    December 2022
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    January 10, 2023 (Anticipated)
    Primary Completion Date
    January 10, 2024 (Anticipated)
    Study Completion Date
    January 10, 2024 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor-Investigator
    Name of the Sponsor
    Michelle Grinman
    Collaborators
    PRESUNA, Institute of Health Economics, Canada, Alberta Boehringer Ingelheim Collaboration

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Single-center, two-arm, parallel, randomized controlled trial comparing enhanced daily assessments for patients with COPD and/or CHF using point of care ultrasound with PRESUNA software (POCUS-PRESUNA) versus standard care provided by home-based acute care through a tertiary acute care medical teaching hospital. The objectives are to evaluate POCUS-PRESUNA on improving patient experience, provider experience, improve healthcare utilization/costs, and to test the feasibility of incorporating longitudinal POCUS assessments in home-based acute care via remotely acquired images by non-physicians.
    Detailed Description
    PRESUNA, a new medical software platform that supports clinicians in optimizing their use of POCUS for CHF and COPD patients in the community, is designed to enhance clinical decision-making and long-term monitoring of patients with CHF and COPD. The aim is to more precisely identify changes in the lungs in order to proactively treat exacerbations and confirm treatment responses. It will also enable practitioners to share information from each scan visually and in a standard format in order to track changes longitudinally. This is expected to reduce potentially avoidable hospitalizations and increase patient quality of life in the community. This study will implement the use of POCUS enhanced by PRESUNA software in the clinical practice of clinicians on a home hospital (HH) program at a tertiary teaching hospital in Calgary, Alberta. On this home hospital, patients are seen and examined either by home visiting community paramedics who consult with the physician, or in-person by physicians in the home hospital clinic space when expedited diagnostic imaging or investigations are required. Objective: To perform a randomized control trial comparing patients with COPD and/or CHF admitted to the HH who will undergo usual care versus usual care enhanced with POCUS and PRESUNA. Methods: Practitioner Recruitment Home hospital clinicians will be provided information about this study in order to obtain informed consent for participation in the study. Physicians who are already POCUS experts will provide informed consent to undergo training on how to use PRESUNA software and to incorporate POCUS into their home hospital care for intervention study patients. Non-POCUS expert clinicians (community paramedics, some of the physicians and nurses) will provide informed consent to undergo group POCUS training and subsequent individual training sessions in order to enable them to become proficient at using POCUS. They will also consent to being trained on how to use PRESUNA software, as well as incorporating POCUS and PRESUNA into their home hospital care for intervention arm patients. Patient Recruitment Patients admitted to HH with CHF and/or COPD will be approached to participate in the research study by the Nurse Navigator or Research Assistant. Those that provide informed consent will be randomized (1:1) to the intervention (POCUS-PRESUNA enhanced HH care) versus control group (usual HH care).

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    COPD, CHF, Pneumonia

    7. Study Design

    Primary Purpose
    Diagnostic
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    Outcomes Assessor
    Allocation
    Randomized
    Enrollment
    44 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    POCUS-PRESUNA
    Arm Type
    Experimental
    Arm Description
    Daily home hospital care will be enhanced by lung POCUS acquired remotely by community paramedics or in-person by physicians, and interpreted by physicians. They will then document their findings on PRESUNA to obtain a longitudinal record that enables monitoring of trends to support clinical decision-making.
    Arm Title
    Standard Care
    Arm Type
    No Intervention
    Arm Description
    Standard home hospital care
    Intervention Type
    Device
    Intervention Name(s)
    Lung point of care ultrasound
    Other Intervention Name(s)
    POCUS
    Intervention Description
    Point of care ultrasound of the lungs will be performed to enhance physical assessments as needed to make clinical decisions for patients with CHF, COPD and/or pneumonia. The majority of images will be acquired and uploaded to a web-based portal by community paramedics in patients' homes and interpreted remotely by hospital-based physicians on call for the home hospital.
    Intervention Type
    Other
    Intervention Name(s)
    PRESUNA software
    Intervention Description
    PRESUNA is a new medical software that enables clinicians to summarize POCUS findings and document them on a platform that provides a visual summary of findings over time. PRESUNA also provides POCUS educators and learners to see the learners' progress over time in terms of the accuracy of their assessments when compared to POCUS experts providing longitudinal mentorship.
    Primary Outcome Measure Information:
    Title
    Length of stay
    Description
    Length of stay for index Home Hospital admission
    Time Frame
    From the date of admission to discharge from the index admission, assessed up to 1 year
    Secondary Outcome Measure Information:
    Title
    Patient outcome - Time to resolution of infection
    Description
    return to baseline oxygen saturation and normalization of white blood cell count
    Time Frame
    Assessed up to 24 months after infection identified
    Title
    Patient outcome - time to decongestion
    Description
    absence of crackles and baseline oxygen saturation on lung examination
    Time Frame
    Assessed up to one year after congestion identified
    Title
    Patient outcome - rate of change in NT-BNP
    Description
    Difference between NT-BNP on admission and at time of decongestion over total number of days
    Time Frame
    Change from admission to when decongestion occurred, assessed up to 12 months
    Title
    Patient outcome - Admission to facility living
    Description
    Proportion of patients in each study arm that required admission to facility living (eg: long-term care, supportive living) after their index admission
    Time Frame
    From date and time of discharge from index admission, assessed up to 12 months
    Title
    Patient outcome - Escalation of care
    Description
    Incidence rate ratio for frequency with which patients are transferred back to the bricks and mortar hospital from the home hospital.
    Time Frame
    From date of randomization until the patient is discharged from the index admission (assessed up to 12 months).
    Title
    Patient outcome - Adverse events
    Description
    Frequency and severity of adverse events (venous thromboembolism, new infections, falls, delirium)
    Time Frame
    From date of randomization until the date of first documented progression or date of death from any cause, whichever came first until the patient is discharged from the hospital (assessed up to 12 months).
    Title
    Patient outcome - Mortality
    Description
    Date and cause of mortality of occurrence of mortality
    Time Frame
    From date of randomization until the date of death, assessed up to 12 months
    Title
    Health Related Quality of Life - EuroQuol- 5-Dimension-5-Level (EQ-5D-5L) -Mobility
    Description
    The ability to mobilize is rated by patients on a scale from 1-5 (1= no problems, 2= slight problems, 3= moderate problems, 4= Severe problems, 5= Unable to perform activity)
    Time Frame
    At time of randomization, within one week of discharge from the index admission, at 3 months post-discharge, and at 6 months post-discharge
    Title
    Health Related Quality of Life - EuroQuol- 5-Dimension-5-Level (EQ-5D-5L) -Activities of daily living
    Description
    Ability to perform activities of daily living rated by patients from 1-5 (1= no problems, 2= slight problems, 3= moderate problems, 4= Severe problems, 5= Unable to perform activity)
    Time Frame
    At time of randomization, within one week of discharge from the index admission, at 3 months post-discharge, and at 6 months post-discharge
    Title
    Health Related Quality of Life - EuroQuol- 5-Dimension-5-Level (EQ-5D-5L) -Pain and discomfort
    Description
    The intensity of pain or discomfort is rated by patients from 1 to 5 (1=none, 2= slight , 3= moderate , 4=severe, 5=extreme).
    Time Frame
    At time of randomization, within one week of discharge from the index admission, at 3 months post-discharge, and at 6 months post-discharge
    Title
    Health Related Quality of Life - EuroQuol- 5-Dimension-5-Level (EQ-5D-5L) -Self care
    Description
    Ability to perform self-care rated from 1= no problems, 2= slight problems, 3= moderate problems, 4= Severe problems, 5= Unable to perform activity
    Time Frame
    At time of randomization, within one week of discharge from the index admission, at 3 months post-discharge, and at 6 months post-discharge
    Title
    Health Related Quality of Life - EuroQuol- 5-Dimension-5-Level (EQ-5D-5L) -Anxiety and Depression
    Description
    Patients rate whether they feel anxious or depressed from 1-5 (1=no, 2= slightly, 3= moderately, 4=severely, 5=extremely).
    Time Frame
    At time of randomization, within one week of discharge from the index admission, at 3 months post-discharge, and at 6 months post-discharge
    Title
    Health Related Quality of Life - EuroQuol- 5-Dimension-5-Level (EQ-5D-5L) -Index Score
    Description
    The index score is computed using the EQ-5D calculator that uses the scores of the individual dimensions (mobility, self-care, activities of daily living, pain and discomfort, anxiety and depression); Scores range between 5-25 with higher scores indicating a worse outcome
    Time Frame
    At time of randomization, within one week of discharge from the index admission, at 3 months post-discharge, and at 6 months post-discharge
    Title
    Health Related Quality of Life - EuroQuol- 5-Dimension-5-Level (EQ-5D-5L) Visual Analogue Scale (EQ-VAS)
    Description
    Participant asked to rate both verbally and visually "where [they] would put [their] health today" on a scale from 0 ("the worst health you can imagine") to 100 ("the best health you can imagine)
    Time Frame
    At time of randomization, within one week of discharge from the index admission, at 3 months post-discharge, and at 6 months post-discharge
    Title
    Patient experience
    Description
    Survey measuring experience with clinical care and various technologies employed by the Home Hospital (digital remote patient monitoring, videoconferencing, as well as POCUS for the intervention arm). This survey was developed by the study team. Responses to questions were either, "yes", "yes, to some extent", "no", and "unsure".
    Time Frame
    Upon discharge from the Home Hospital (up to 7 business days post-discharge)
    Title
    Provider experience
    Description
    Surveys including experience providing care for patients on each study arm and experience with various technologies employed in the home hospital program (digital remote patient monitoring, videoconferencing, as well as POCUS and PRESUNA for the intervention arm). This survey was developed by the study team. Responses were on a Likert scale, which included "strongly disagree", "disagree", "neither agree/nor disagree", "agree" and "strongly agree"
    Time Frame
    Within 1 week of being on the Hospital at Home service
    Title
    Healthcare utilization cost - Diagnostic testing
    Description
    Cost of Diagnostic testing
    Time Frame
    Between the date and time of hospital admission to up to 3 months post-discharge
    Title
    Healthcare utilization - Incidence rate ratio of acute care days pre/during/post
    Description
    Incidence rate ratio of acute care days in the bricks and mortar hospital 90 days pre-randomization, during the index admission after randomization, and 90 days post discharge from index admission
    Time Frame
    90 days before randomization until 90 days after index admission (assessed up to 15 months)
    Title
    Healthcare utilization - Incidence rate ratio of ED/Urgent Care visits pre/during/post
    Description
    Incidence rate ratio of ED and urgent care visits- 90 days pre-randomization, during the index admission after randomization, and 90 days post discharge from index admission
    Time Frame
    90 days before, during and 90 days after index admission
    Title
    Cost analysis
    Description
    Incremental effectiveness ratio for the index admission
    Time Frame
    From date of admission until the date of discharge from the index admission, assessed up to 12 months").
    Title
    Cost analysis
    Description
    Incremental effectiveness ratio for healthcare utilization post-discharge
    Time Frame
    From date of discharge from index admission, assessed up to 90 days.

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Patient Inclusion Criteria: 18 years of age or older Has a provincial health care number Functionally safe to receive HH care or have sufficient caregiving to support them at home Stable enough to be cared for at home - stable vital signs and requiring no more than 2 visits per day Able and willing to follow a management plan Provides consent to receive care on HH Diagnosis of CHF and/or COPD that requires HH care No painful/broken ribs that could be affected by pressure applied when performing lung POCUS Patient Exclusion Criteria: Not eligible for HH care New unstable rib fractures Prior history of allergy to ultrasound gel Participant refusal to participate in research study Provider inclusion criteria Attending clinician on the home hospital program within the next 3-6 months Provides informed consent to participate in the study, including necessary training for the use of POCUS and/or PRESUNA Provider exclusion criteria Not a home hospital clinician Refuses to consent for the study / training.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Michelle Grinman, MD FRCPC MPH
    Phone
    403.943.3889
    Email
    michelle.grinman@ucalgary.ca
    First Name & Middle Initial & Last Name or Official Title & Degree
    Steve Reid, BEng
    Phone
    403.305.7295
    Email
    steve.reid@presuna.com
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Michelle Grinman, MD FRCPC MPH
    Organizational Affiliation
    University of Calgary
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Aiding COPD and CHF Ultrasound-guided Management Through ENhanced Point Of Care UltraSound

    We'll reach out to this number within 24 hrs